BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20587403)

  • 1. Novel treatment approaches for triple-negative breast cancer.
    Telli ML; Ford JM
    Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
    Curigliano G; Goldhirsch A
    J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer.
    Bartsch R; Ziebermayr R; Zielinski CC; Steger GG
    Wien Med Wochenschr; 2010 Apr; 160(7-8):174-81. PubMed ID: 20473728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options for triple-negative breast cancers with defective homologous recombination.
    Jaspers JE; Rottenberg S; Jonkers J
    Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for triple-negative breast cancer: where are we?
    Duffy MJ; McGowan PM; Crown J
    Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer: disease entity or title of convenience?
    Carey L; Winer E; Viale G; Cameron D; Gianni L
    Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2010; 15 Suppl 5():49-56. PubMed ID: 21138955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the heterogeneity of triple-negative breast cancer.
    Metzger-Filho O; Tutt A; de Azambuja E; Saini KS; Viale G; Loi S; Bradbury I; Bliss JM; Azim HA; Ellis P; Di Leo A; Baselga J; Sotiriou C; Piccart-Gebhart M
    J Clin Oncol; 2012 May; 30(15):1879-87. PubMed ID: 22454417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors and their role in the therapy of triple-negative metastatic breast cancer].
    Kozioł M; Püsküllüoglu M; Zygulska A
    Przegl Lek; 2012; 69(6):265-70. PubMed ID: 23094440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    Drew Y; Plummer R
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):67-71. PubMed ID: 19934756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
    Shibata H; Miuma S; Saldivar JC; Huebner K
    Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancer: a brief review of its characteristics and treatment options.
    Griffiths CL; Olin JL
    J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.